Eileen Joyce (United Kingdom)

UCL Queen Square Institute of Neurology Clinical and Movement Neurosciences
Eileen Joyce is a Professor of Neuropsychiatry at The Institute of Neurology, University College London. Her current research focuses on interventions for neuropsychiatric disorders such as schizophrenia, OCD and Tourette’s syndrome and their mechanisms of action. Her clinic work includes the management of complex neuropsychiatric disorders such as conversion disorder, Parkinson’s disease and Tourette’s syndrome. She is involved in clinical studies of deep brain stimulation and neurosurgical ablation for severe mental illness. Professor Joyce obtained her first degree in Experimental Psychology and PhD in dopamine psychopharmacology from the University of Cambridge. She then went on to study medicine also at Cambridge. She trained in psychiatry at the Bethlem and Maudsley Hospitals and spent several years as a research worker at the Institute of Psychiatry, where she was a Wellcome Trust Lecturer in Mental Health. This was followed by time at the USA National Institutes of Health. She was Professor of Neuropsychiatry at Imperial College London before to moving to UCL. She is immediate past Chair of the Faculty of Neuropsychiatry, Royal College of Psychiatrists, London and current Chair of the International Neuropsychiatry Association.

Author Of 2 Presentations

Free Communication

SPECTRUM, RISK FACTORS AND OUTCOMES OF NEUROLOGICAL COMPLICATIONS OF COVID-19

Session Type
Free Communication
Date
06.10.2021, Wednesday
Session Time
11:30 - 13:00
Room
Free Communication A
Lecture Time
12:30 - 12:40
Presenter
  • Marc Hardwick (United Kingdom)

Abstract

Background and Aims:

SARS-CoV2 is associated with neurological and psychiatric complications including cerebrovascular events, encephalopathy and peripheral nerve disease. Detailed clinical data is lacking, hampering prediction modelling and targeted therapeutic interventions.

Methods:

We conducted a UK-wide cross-sectional surveillance study of 267 adult hospitalised patients with SARS-CoV2 infection and neurological and psychiatric complications. Detailed demographic and clinical data was provided by reporting physicians from multiple specialities. A priori clinical case definitions were used, with cross-specialty adjudication for discrepant cases.

Results:

Cerebrovascular events were most frequent (n=131), followed by delirium (n=28), central inflammatory (n=25), psychiatric (n=25), and other encephalopathies (n=17), including a severe encephalopathy (n=13) not meeting delirium criteria; and peripheral nerve disease (n=41). COVID-19 associated strokes were younger and had more conventional risk factors compared to pre-pandemic normative data. 27% of strokes occurred in patients under 60 years old: these had delayed onset from respiratory symptoms, higher rates of multi-vessel occlusion (31%) and systemic thrombotic events. Cases with severe encephalopathy were younger and had a greater usage of intensive care compared to delirium. In a multivariable model, increasing age, pre-admission frailty and admission white cell count were more predictive of negative outcomes than diagnostic group.

Conclusions:

COVID-19-associated stroke is more likely to affect younger patients with conventional risk factors, and with a distinct phenotype suggestive of systemic coagulopathy. There is consensus recognition of severe encephalopathy atypical for delirium occuring in patients with severe COVID-19. Overall, pre-morbid factors have the greatest effect on outcome. These findings will inform mechanistic studies and patient stratification in future clinical trials.

Hide
Scientific Session: T (Topics)

CONTROVERSIES IN NEUROPSYCHIATRY: DEEP BRAIN STIMULATION FOR SEVERE MENTAL ILLNESS

Session Type
Scientific Session: T (Topics)
Date
06.10.2021, Wednesday
Session Time
09:30 - 11:00
Room
Topic A
Lecture Time
10:16 - 10:39
Presenter
  • Eileen Joyce (United Kingdom)

Abstract

Abstract Body

Deep brain stimulation (DBS) has been available for neurological conditions such as Parkinson’s disease and dystonia for over 20 years and is an approved treatment in many countries. DBS for severe mental illness was also first described decades ago, for OCD in 1999 and depression in 2005. However, it is not widely available for these indications as a health-service treatment and remains largely experimental. The reasons include: debate about the best target; acceptability of neurosurgery to psychiatrists and patients; and failures of randomised controlled trials off DBS for depression. This presentation will provide an overview of the controversies in DBS for mental illness, an update of recent evidence concerning brain targets and a discussion of future directions.

Hide

Presenter of 1 Presentation

Scientific Session: T (Topics)

CONTROVERSIES IN NEUROPSYCHIATRY: DEEP BRAIN STIMULATION FOR SEVERE MENTAL ILLNESS

Session Type
Scientific Session: T (Topics)
Date
06.10.2021, Wednesday
Session Time
09:30 - 11:00
Room
Topic A
Lecture Time
10:16 - 10:39
Presenter
  • Eileen Joyce (United Kingdom)

Abstract

Abstract Body

Deep brain stimulation (DBS) has been available for neurological conditions such as Parkinson’s disease and dystonia for over 20 years and is an approved treatment in many countries. DBS for severe mental illness was also first described decades ago, for OCD in 1999 and depression in 2005. However, it is not widely available for these indications as a health-service treatment and remains largely experimental. The reasons include: debate about the best target; acceptability of neurosurgery to psychiatrists and patients; and failures of randomised controlled trials off DBS for depression. This presentation will provide an overview of the controversies in DBS for mental illness, an update of recent evidence concerning brain targets and a discussion of future directions.

Hide

Moderator of 1 Session

Scientific Session: T (Topics)
Session Time
11:30 - 13:00
Room
Topic A
Chair(s)
  • Eileen Joyce (United Kingdom)